01—Abstract
Summary
Summary of the 10-Q filed July 23, 2026. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. reported a strong second quarter of 2026, with total revenue of $707.3 milliona for the three months ended June 30, 2026, up from $603.3 million a year earlier, and $1,413.9 million for the six months, up from $1,161.9 million.
Net income was $121.4 millionb for the quarter versus $90.3 million, and diluted EPS was $4.25 versus $3.10. Growth was attributed primarily to the Metabolic, Oncology, Central Nervous System and AVAI therapeutic areas. Reimbursed out-of-pocket expenses, which fluctuate with program timing, rose sharply and drove much of the increase in total direct costs.
Net new business awards were $795.7 millionc for the quarter and $1,414.2 million for the six months, and backlog stood at $3,014.2 million as of June 30, 2026. Cash and cash equivalents were $502.7 million at quarter end, and the company has no indebtedness, with a $10.0 million credit facility fully available. Operating cash flow for the first six months was $313.8 million, while the company spent $294.8 million on share repurchases during the period.
Shares outstanding fell from 28,370,780 at December 31, 2025 to 27,910,605 at June 30, 2026, and shareholders' equity declined to $433.9 milliond from $459.1 million. Remaining repurchase authorization totaled $527.0 million.
The filing also discloses two shareholder lawsuits filed in April and June 2026 relating to statements about the company's book-to-bill ratio. The company has not recognized a liability for either matter, stating that any potential loss is not currently probable or reasonably estimable.
02—Key points
Key Highlights
- Total revenue rose to $707.3 million in Q2 2026 from $603.3 million in Q2 2025; six-month revenue reached $1,413.9 million versus $1,161.9 million.
- Net income was $121.4 million for the quarter (diluted EPS $4.25) versus $90.3 million (diluted EPS $3.10) a year earlier.
- Backlog increased to $3,014.2 million as of June 30, 2026 from $2,873.6 million a year earlier; net new business awards were $795.7 million for the quarter.
- Cash and cash equivalents were $502.7 million, and the company reported no indebtedness under its $10.0 million unsecured Credit Facility.
- The company repurchased 705,616 shares for $294.7 million in the quarter, leaving $527.0 million of remaining authorization.
- Operating cash flow was $313.8 million for the six months ended June 30, 2026, compared with $274.4 million a year earlier.
- Two shareholder lawsuits filed in April and June 2026 relate to statements about the book-to-bill ratio; no liability has been recognized for either.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed July 23, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $707.33M$603.31M | +17.2% |
| SG&A Expenses | $48.10M$46.66M | +3.1% |
| Operating Expenses | $560.51M$476.98M | +17.5% |
| Operating Income | $146.82M$126.33M | +16.2% |
| Net Income | $121.36M$90.26M | +34.5% |
| EPS (Basic) | $4.31$3.16 | +36.4% |
| EPS (Diluted) | $4.25$3.10 | +37.1% |
| Shares Outstanding (Basic) | 28.17M28.60M | −1.5% |
| Shares Outstanding (Diluted) | 28.55M29.14M | −2.0% |
05—Questions
Frequently Asked Questions
What drove the revenue increase in the second quarter of 2026?
The filing states that the increase was primarily driven by growth within the Metabolic, Oncology, Central Nervous System and AVAI therapeutic areas compared with the same period in the prior year. Revenue for the quarter was $707.3 million, up from $603.3 million.
Why did total direct costs rise faster than revenue?
Total direct costs increased $82.4 million to $505.7 million for the quarter. The filing attributes this mainly to higher reimbursed out-of-pocket expenses, which rose $65.7 million and can fluctuate significantly based on the timing of program initiation and closeout, along with higher personnel costs to support service growth.
What is the company's liquidity position and debt status?
As of June 30, 2026, cash and cash equivalents were $502.7 million, with about $26.3 million held by foreign subsidiaries. The company had no indebtedness, and its $10.0 million revolving credit facility was fully available. Management believes its liquidity is sufficient for the next 12 months.
How much did the company return to shareholders, and what remains under the buyback program?
During the first six months of 2026, the company repurchased shares for $294.8 million in cash. As of June 30, 2026, remaining authorization under the share repurchase program was $527.0 million.
What legal matters does the filing disclose?
Two shareholder complaints are disclosed, both concerning statements about the company's book-to-bill ratio. One is a securities class action filed April 6, 2026 in the Southern District of Ohio, and the other is a stockholder derivative action filed June 22, 2026. The filing states that no liability has been recognized because any potential loss is not currently probable or reasonably estimable.
06—Continue